{"product_id":"igf-1-lr3-long-r3-igf-1-peptide-intelligence-monograph-fime","title":"IGF-1 LR3 (Long R3 IGF-1) Peptide Intelligence Monograph | FIME","description":"\u003cdiv class=\"relative basis-auto flex-col -mb-(--composer-overlap-px) pb-(--composer-overlap-px) [--composer-overlap-px:28px] grow flex\"\u003e\n\u003cdiv class=\"flex min-h-0 grow flex-col text-sm\"\u003e\n\u003cdiv class=\"qMYqUG_convSearchResultHighlightRoot\"\u003e\n\u003cdiv class=\"\"\u003e\n\u003csection class=\"text-token-text-primary w-full focus:outline-none has-data-writing-block:pointer-events-none [\u0026amp;:has([data-writing-block])\u0026gt;*]:pointer-events-auto R6Vx5W_threadScrollVars scroll-mb-[calc(var(--scroll-root-safe-area-inset-bottom,0px)+var(--thread-response-height))] scroll-mt-[calc(var(--header-height)+min(200px,max(70px,20svh)))]\" dir=\"auto\"\u003e\n\u003cdiv class=\"text-base my-auto mx-auto pb-8 [--thread-content-margin:var(--thread-content-margin-xs,calc(var(--spacing)*4))] @w-sm\/main:[--thread-content-margin:var(--thread-content-margin-sm,calc(var(--spacing)*6))] @w-lg\/main:[--thread-content-margin:var(--thread-content-margin-lg,calc(var(--spacing)*16))] px-(--thread-content-margin)\"\u003e\n\u003cdiv class=\"[--thread-content-max-width:40rem] @w-lg\/main:[--thread-content-max-width:48rem] mx-auto max-w-(--thread-content-max-width) flex-1 group\/turn-messages focus-visible:outline-hidden relative flex w-full min-w-0 flex-col agent-turn\"\u003e\n\u003cdiv class=\"flex max-w-full flex-col gap-4 grow\"\u003e\n\u003cdiv dir=\"auto\" class=\"min-h-8 text-message relative flex w-full flex-col items-end gap-2 text-start break-words whitespace-normal outline-none keyboard-focused:focus-ring [.text-message+\u0026amp;]:mt-1\" tabindex=\"0\"\u003e\n\u003cdiv class=\"flex w-full flex-col gap-1 empty:hidden\"\u003e\n\u003cdiv class=\"markdown prose dark:prose-invert wrap-break-word w-full light markdown-new-styling\"\u003e\n\u003cp class=\"PDq2pG_selectionAnchorContainer\"\u003e\u003cstrong\u003eIGF-1R Signaling • Anabolic Biology • Skeletal Muscle Research • Glucose Metabolism • Growth Signaling\u003c\/strong\u003e\u003cspan class=\"PDq2pG_selectionAnchor\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003eIGF-1 LR3 sits at the intersection of some of the most powerful biology in human physiology:\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003egrowth, metabolism, muscle adaptation, cellular survival, and tissue signaling.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAlso known as \u003cstrong\u003eLong R3 IGF-1\u003c\/strong\u003e, this engineered analogue was designed to interact differently with IGF-binding proteins while retaining activity at the IGF-1 receptor.\u003c\/p\u003e\n\u003cp\u003eThat modification matters.\u003c\/p\u003e\n\u003cp\u003eIt also creates one of the easiest evidence traps in the peptide marketplace.\u003c\/p\u003e\n\u003cp\u003eThe human \u003cstrong\u003eIGF-1 pathway\u003c\/strong\u003e is extremely well studied.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eMecasermin\u003c\/strong\u003e, recombinant human IGF-1, has legitimate clinical evidence and FDA-approved use for specific pediatric indications.\u003c\/p\u003e\n\u003cp\u003eBut IGF-1 LR3 is a different molecule.\u003c\/p\u003e\n\u003cp\u003eThe \u003cstrong\u003eFounder’s Institute of Medicine \u0026amp; Education IGF-1 LR3 Peptide Intelligence Monograph\u003c\/strong\u003e examines where established IGF-1 biology ends—and where claims about LR3 begin.\u003c\/p\u003e\n\u003ch3\u003eInside the Monograph\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eWhat IGF-1 is\u003c\/li\u003e\n\u003cli\u003eWhat makes Long R3 IGF-1 different\u003c\/li\u003e\n\u003cli\u003eThe significance of reduced IGF-binding-protein affinity\u003c\/li\u003e\n\u003cli\u003eIGF-1 receptor signaling\u003c\/li\u003e\n\u003cli\u003ePI3K\/AKT\/mTOR pathways\u003c\/li\u003e\n\u003cli\u003eRAS\/RAF\/MEK\/ERK signaling\u003c\/li\u003e\n\u003cli\u003eSkeletal-muscle anabolic biology\u003c\/li\u003e\n\u003cli\u003eSatellite-cell research\u003c\/li\u003e\n\u003cli\u003eHuman recombinant IGF-1 evidence\u003c\/li\u003e\n\u003cli\u003eThe role of mecasermin\u003c\/li\u003e\n\u003cli\u003eWhy \u003cstrong\u003emecasermin ≠ IGF-1 LR3\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eBodybuilding and performance claims\u003c\/li\u003e\n\u003cli\u003e“Site-specific growth” claims\u003c\/li\u003e\n\u003cli\u003eFat-loss and nutrient-partitioning claims\u003c\/li\u003e\n\u003cli\u003eGlucose metabolism\u003c\/li\u003e\n\u003cli\u003eHypoglycemia concerns\u003c\/li\u003e\n\u003cli\u003eProliferative signaling and cancer biology\u003c\/li\u003e\n\u003cli\u003eOrgan and soft-tissue growth questions\u003c\/li\u003e\n\u003cli\u003eEndocrine feedback\u003c\/li\u003e\n\u003cli\u003eLong-term safety limitations\u003c\/li\u003e\n\u003cli\u003eResearch-market product quality\u003c\/li\u003e\n\u003cli\u003eRegulatory status\u003c\/li\u003e\n\u003cli\u003eFIME evidence grading and clinical translation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eThe Evidence Firewall\u003c\/h3\u003e\n\u003cp\u003eThis monograph preserves three separate evidence categories:\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eIGF-1 physiology\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eMecasermin clinical evidence\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eIGF-1 LR3 evidence\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThese are related.\u003c\/p\u003e\n\u003cp\u003eThey are not interchangeable.\u003c\/p\u003e\n\u003cp\u003eHuman data showing that recombinant IGF-1 can affect lean mass, metabolism, or growth do not establish the same outcomes for LR3.\u003c\/p\u003e\n\u003cp\u003eLikewise, FDA approval of mecasermin does not extend to Long R3 IGF-1.\u003c\/p\u003e\n\u003ch3\u003eWhy LR3 Is Different\u003c\/h3\u003e\n\u003cp\u003eLR3 is an engineered analogue with:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ean amino-acid substitution at position 3\u003c\/li\u003e\n\u003cli\u003ean added N-terminal extension\u003c\/li\u003e\n\u003cli\u003emarkedly reduced affinity for IGF-binding proteins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThat altered binding behavior is central to its experimental profile.\u003c\/p\u003e\n\u003cp\u003eIt was designed to change how IGF activity is regulated—not merely to recreate native physiology.\u003c\/p\u003e\n\u003ch3\u003eAnabolic Potential vs. Human Proof\u003c\/h3\u003e\n\u003cp\u003eIGF-1R signaling is deeply involved in:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eprotein synthesis\u003c\/li\u003e\n\u003cli\u003emuscle-cell growth\u003c\/li\u003e\n\u003cli\u003esatellite-cell biology\u003c\/li\u003e\n\u003cli\u003ecellular survival\u003c\/li\u003e\n\u003cli\u003etissue repair\u003c\/li\u003e\n\u003cli\u003emetabolic signaling\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis gives LR3 strong \u003cstrong\u003emechanistic anabolic plausibility\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eBut:\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eanabolic plausibility ≠ demonstrated human hypertrophy\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ecell signaling ≠ proven athletic performance\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eanimal\/cellular evidence ≠ validated bodybuilding therapy\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere is no mature controlled human evidence establishing LR3 as a safe and effective muscle-building or performance-enhancement drug.\u003c\/p\u003e\n\u003ch3\u003eHypoglycemia Matters\u003c\/h3\u003e\n\u003cp\u003eIGF biology interacts meaningfully with glucose metabolism.\u003c\/p\u003e\n\u003cp\u003eHypoglycemia is a known clinical concern with pharmaceutical recombinant IGF-1.\u003c\/p\u003e\n\u003cp\u003eThat makes low blood glucose a legitimate mechanistic safety concern for LR3.\u003c\/p\u003e\n\u003cp\u003eBut without adequate human LR3 trials, the actual:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eincidence\u003c\/li\u003e\n\u003cli\u003eseverity\u003c\/li\u003e\n\u003cli\u003edose relationship\u003c\/li\u003e\n\u003cli\u003eand long-term metabolic consequences\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eremain unknown.\u003c\/p\u003e\n\u003ch3\u003eGrowth Signaling Is Systemic\u003c\/h3\u003e\n\u003cp\u003eAnother important point:\u003c\/p\u003e\n\u003cp\u003eA systemic growth factor does not know that the intended target is skeletal muscle.\u003c\/p\u003e\n\u003cp\u003eIGF-1R signaling also influences:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ecellular survival\u003c\/li\u003e\n\u003cli\u003eproliferation\u003c\/li\u003e\n\u003cli\u003eorgan biology\u003c\/li\u003e\n\u003cli\u003econnective tissues\u003c\/li\u003e\n\u003cli\u003emetabolism\u003c\/li\u003e\n\u003cli\u003eand other growth-responsive tissues\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThat is why “muscle growth” and “systemic growth signaling” should not be treated as the same thing.\u003c\/p\u003e\n\u003ch3\u003eCancer Biology: What Can We Actually Say?\u003c\/h3\u003e\n\u003cp\u003eIGF-1R signaling is involved in proliferation and survival pathways that are relevant to oncology.\u003c\/p\u003e\n\u003cp\u003eThat does \u003cstrong\u003enot\u003c\/strong\u003e prove that IGF-1 LR3 causes cancer.\u003c\/p\u003e\n\u003cp\u003eBut it also means we cannot responsibly claim that chronic LR3 exposure is oncologically safe.\u003c\/p\u003e\n\u003cp\u003eThe correct conclusion is:\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eThe proliferative concern is mechanistically credible. The magnitude of human LR3 risk is unknown.\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch3\u003eFIME Evidence Perspective\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eHuman IGF-1 Physiology:\u003c\/strong\u003e Strong\u003cbr\u003e\u003cstrong\u003eIGF-1R Mechanistic Biology:\u003c\/strong\u003e Strong\u003cbr\u003e\u003cstrong\u003eLR3 Reduced IGFBP Affinity:\u003c\/strong\u003e Strong\u003cbr\u003e\u003cstrong\u003eLR3 IGF-1R Activation:\u003c\/strong\u003e Strong — Preclinical\u003cbr\u003e\u003cstrong\u003eLR3 Anabolic Plausibility:\u003c\/strong\u003e Strong — Mechanistic\u003cbr\u003e\u003cstrong\u003eLR3 Animal \/ Cellular Evidence:\u003c\/strong\u003e Moderate\u003cbr\u003e\u003cstrong\u003eHuman LR3 Muscle-Growth Efficacy:\u003c\/strong\u003e Not Established\u003cbr\u003e\u003cstrong\u003eHuman LR3 Performance Efficacy:\u003c\/strong\u003e Not Established\u003cbr\u003e\u003cstrong\u003eHuman LR3 Metabolic Safety:\u003c\/strong\u003e Not Established\u003cbr\u003e\u003cstrong\u003eLong-Term Oncologic Safety:\u003c\/strong\u003e Not Established\u003cbr\u003e\u003cstrong\u003eCommercial Product Evidence:\u003c\/strong\u003e Not Established\u003cbr\u003e\u003cstrong\u003eFDA-Approved LR3 Indication:\u003c\/strong\u003e None\u003c\/p\u003e\n\u003ch3\u003eWhy This Monograph Matters\u003c\/h3\u003e\n\u003cp\u003eIGF-1 LR3 borrows credibility very easily from one of the most thoroughly studied growth systems in medicine.\u003c\/p\u003e\n\u003cp\u003eThat is exactly why evidence discipline matters.\u003c\/p\u003e\n\u003cp\u003eThe pathway is real.\u003c\/p\u003e\n\u003cp\u003eThe signaling is real.\u003c\/p\u003e\n\u003cp\u003eThe anabolic rationale is real.\u003c\/p\u003e\n\u003cp\u003eThe exact molecule still has to prove itself in humans.\u003c\/p\u003e\n\u003ch3\u003eThe FIME Bottom Line\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eStrong underlying human biology.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eStrong mechanistic rationale.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eBiologically active engineered analogue.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eMeaningful preclinical evidence.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eNo established human LR3 efficacy.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eNo established human LR3 safety profile.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImportant unresolved metabolic and proliferative risks.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cblockquote\u003e\n\u003cp\u003e\u003cstrong\u003eIGF-1 LR3 borrows credibility easily from one of the best-established growth pathways in medicine. The molecule itself still has to earn that credibility in humans.\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003ch3\u003eThe FIME Standard\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eEvidence over hype.\u003cbr\u003eScience over claims.\u003cbr\u003eIntegrity over revenue.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eVersion 1.0 Final\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePublished by the \u003cstrong\u003eFounder’s Institute of Medicine \u0026amp; Education\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003eFor professional education and scientific review. Not individualized medical advice, a prescription, bodybuilding or athletic-performance guidance, or a treatment protocol. IGF-1 LR3 does not have an established FDA-approved therapeutic indication.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"mt-3 w-full empty:hidden has-[\u0026gt;_:empty]:hidden\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"[--thread-content-max-width:40rem] @w-lg\/main:[--thread-content-max-width:48rem] mx-auto max-w-(--thread-content-max-width) flex-1\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"mt-auto grid\"\u003e\n\u003cdiv class=\"col-start-1 row-start-1\"\u003e\u003c\/div\u003e\n\u003cdiv class=\"sticky bottom-(--scroll-root-safe-area-inset-bottom,0px) col-start-1 row-start-1 self-end\"\u003e\n\u003cdiv class=\"\"\u003e\n\u003cdiv class=\"min-h-9 pt-2 text-center text-xs text-token-text-tertiary [view-transition-name:var(--vt-disclaimer)] pb-4 relative overflow-hidden @w-sm\/main:px-[60px]\"\u003e\n\u003cdiv class=\"text-base mx-auto [--thread-content-margin:var(--thread-content-margin-xs,calc(var(--spacing)*4))] @w-sm\/main:[--thread-content-margin:var(--thread-content-margin-sm,calc(var(--spacing)*6))] @w-lg\/main:[--thread-content-margin:var(--thread-content-margin-lg,calc(var(--spacing)*16))] px-(--thread-content-margin)\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Founder's Institute of Medicine \u0026 Education","offers":[{"title":"Default Title","offer_id":45385080307894,"sku":null,"price":24.95,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0736\/0990\/4310\/files\/ChatGPTImageAug26_2026_02_10_09PM.png?v=1787782473","url":"https:\/\/foundersinstitutemed.org\/products\/igf-1-lr3-long-r3-igf-1-peptide-intelligence-monograph-fime","provider":"Founder's Institute of Medicine \u0026 Education","version":"1.0","type":"link"}